 |
|
 |
- July 4, 2008 |
|
|
Welcome to the #1 online source of information for Diabetes Specialists! An international online community of more than 10,000 Diabetes Specialists.
CME on Diabetes is a website built to transmit top-level CME conferences given by international experts in endocrinology, insulin resistance, prediabetes, metabolic syndrome and type 2 diabetes. More than 2.6 million slides have been viewed since the website launch. Thank you for your continued support and commitment!
|
|
|
| Presentation |
|
"Could you please comment on recent clinical trials of cardiovascular events in patients with type 2 diabetes?"Dr. Andrew P. Selwyn (biography)
English - 2004-06-04 - 16 minutes
|
 | (9 slides) |
Summary :
Recent studies of prevention of cardiovascular events with lipid-lowering therapy include the PROVE-IT (Pravastatin or Atorvastatin Evaluation and Infection Therapy) trial and the CARDS (Collaborative AtoRvastatin Diabetes Study).
The PROVE-IT trial was conducted in over 4000 patients over 30 months of follow up, and showed the superiority of an intensive lipid-lowering therapy with atorvastatin compared to standard therapy with pravastatin, in reducing the incidence of death or major cardiovascular events in patients having recently had an acute coronary syndrome.
The CARDS study looked at primary prevention of cardiovascular disease (CVD) in 2838 patients with type 2 diabetes having at least one other CVD risk factor. A total risk reduction of 37% was observed in the incidence of major cardiovascular events.
Copyright © 2004 E-MedHosting.com Inc.
Learning objectives :
After viewing these slides the participant will be able to discuss:
- The benefit of intensive lipid-lowering therapy in subjects having undergone an acute coronary syndrome (PROVE-IT study)
- The benefit of lipid-lowering therapy for the primary prevention of CVD in type 2 diabetic patients having at least one other CVD risk factor (CARDS study).
Bibliographic references :
Christopher P. Cannon, M.D., Eugene Braunwald, M.D., Carolyn H. McCabe, B.S., Daniel J. Rader, M.D., Jean L. Rouleau, M.D., Rene Belder, M.D., Steven V. Joyal, M.D., Karen A. Hill, B.A., Marc A. Pfeffer, M.D., Ph.D., Allan M. Skene, Ph.D., for the Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes NEJM.2004;350:1495-1504.
H. M. Colhoun, M. J. Thomason, M. I. Mackness*, S. M. Maton, D. J. Betteridge, P. N. Durrington*, G. A. Hitman§, H. A. W. Neil¶, J. H. Fuller andthe CARDS Investigators.Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetesDiabetic Medicine. 2002;19(3):201.
|
|
|
|
|
|
| Search our website |
 |
| |
Would you like to know more about insulin resistance? Are you looking for information pertaining to Type 2 Diabetes? You can find what you are looking for in over 2000 references available on CMEonDiabetes. |
| |
|
|
| Social |
|
| |
Let others know about this presentation.
|
|
|
|
